45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Gibson
Angelia D
AD
Klem
Jennifer
J
Price
Nancy
N
Reddy
G Kesava
GK
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D006405:Hematology / Q000639:trends*; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy; D010087:Oxides / Q000008:administration & dosage; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000097:blood; D012008:Recurrence; D012306:Risk; D000069283:Rituximab; D016879:Salvage Therapy; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D051746:ZAP-70 Protein-Tyrosine Kinase
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001152:Arsenicals; D010087:Oxides; D000069283:Rituximab; D013792:Thalidomide; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D000077269:Lenalidomide; D000077237:Arsenic Trioxide